214 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
While specific findings are not yet available, this study's design is crucial for understanding the feasibility of transitioning Type 2 Diabetes patients to sustained-release GLP-1R agonist therapies. If ITCA 650 prov…
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obe…
This study provides compelling evidence that liraglutide could be a viable therapeutic strategy for preventing or treating postoperative cognitive dysfunction in elderly patients. The identified mechanism, involving t…
This study provides compelling evidence that an intensive, short-term metabolic intervention can lead to sustained remission of Type 2 Diabetes, moving beyond mere disease management. The combination of IDegLira, metf…
This systematic review provides compelling evidence that GLP1RAs offer a crucial therapeutic strategy for improving cardiovascular outcomes in a high-risk population previously less studied: obese individuals with ASC…
Liraglutide shows direct chondroprotective potential by simultaneously reducing inflammation and promoting cartilage repair markers in human cells. This suggests a dual therapeutic mechanism for OA beyond its establis…
First-in-human Phase 2 trial of GSK2890457 investigated its safety, tolerability, and pharmacodynamics in healthy volunteers and Type 2 Diabetes subjects.
Understanding GLP-1's direct vascular effects could significantly expand its therapeutic potential beyond mere glucose control, offering new avenues for patient care. If GLP-1 or its analogues demonstrate independent …
Lixisenatide and Liraglutide's pharmacodynamic effects on post-prandial glucose and C-peptide were compared in 142 T2DM patients on insulin glargine.
This study design highlights a critical need to understand how different incretin-based therapies impact Type 2 Diabetes management, especially in diverse populations. While the specific results are not detailed, the …
Investigating liraglutide's role in acute myocardial infarction and reperfusion injury holds significant clinical promise, given the ongoing challenge of mitigating post-reperfusion damage despite advancements in PCI.…
A randomized controlled trial investigated Liraglutide's effects on chylomicron/VLDL kinetics, liver fat, and de novo lipogenesis in type 2 diabetes.
If the hypothesis proves true, combining Liraglutide with LSG could establish a new standard for post-bariatric care, offering superior and more durable metabolic improvements for obese patients. Augmenting weight los…
This study provides compelling real-world evidence that GLP-1 Receptor Agonist therapy offers substantial cardiorenal protection in Type 1 Diabetes patients, mirroring benefits previously observed in T2D. These findin…
This study is critically important for enhancing patient safety during surgical procedures for individuals using GLP-1 RAs. The findings will directly inform updated preoperative fasting guidelines, potentially preven…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
This comprehensive "Evidence Map" highlights the transformative potential of incretin-based anti-obesity medications as a crucial therapeutic strategy for women suffering from PCOS and obesity. By consolidating existi…
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
This study is significant because it sought to directly investigate the anti-inflammatory and chondroprotective (cartilage-protecting) potential of liraglutide, a GLP-1 receptor agonist, in knee osteoarthritis beyond …
The progressive decline of beta-cell function is a hallmark of Type 2 Diabetes Mellitus (T2DM), often leading to increased insulin dependence and uncontrolled blood sugar. If liraglutide were shown to preserve beta-ce…
The successful demonstration of bioequivalence means that this new Liraglutide injection can be considered therapeutically interchangeable with Victoza®. This is a significant step towards increasing patient access to…
This study is significant because it addresses a critical unmet need for effective and manageable weight loss interventions in a highly complex and often overlooked patient population. The successful completion of the…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
The withdrawal of this trial highlights the challenges in conducting long-term comparative studies on established diabetes treatments. While this specific study yielded no results, the underlying question of how diffe…
If liraglutide proves effective in improving lung function, it would represent a significant pleiotropic benefit beyond its established role in glucose control and weight management for Type 2 Diabetes Mellitus patien…
This finding is significant because it confirms that liraglutide can reach the central nervous system (CNS), providing a physiological basis for its observed central effects on appetite regulation, glucose homeostasis…
Obstructive sleep apnoea significantly impacts quality of life and carries substantial health risks, particularly in obese populations. Liraglutide, a GLP-1 analogue, is already approved for weight management and type…
This multicentre, non-interventional study provides invaluable real-world evidence on Liraglutide (Saxenda®) safety and effectiveness, which is critical for understanding its performance outside of controlled clinical…
If the collected data demonstrates positive outcomes, this study could establish liraglutide, a GLP-1 receptor agonist, as a novel neuroprotective treatment for diabetic neuropathy. This would be a significant advance…
This trial design is significant because chronic heart failure and type 2 diabetes represent a substantial global health burden, and understanding how GLP-1 (glucagon-like peptide-1) agonists impact cardiac function c…
This study highlights the potential for IDegLira to significantly improve the quality of life for very old patients with Type 2 Diabetes by streamlining their treatment. Simplifying medication regimens can enhance adh…
This research provides compelling evidence that combining Liraglutide with Atorvastatin offers a synergistic therapeutic strategy for managing metabolic dysfunction, inflammation, and oxidative stress. The identificat…
This study provides compelling direct evidence that GLP-1 RAs acutely enhance the contractility of human heart muscle, independent of their systemic metabolic effects. This direct positive inotropic effect could be a …
This comprehensive review underscores the critical role of the gut microbiome as a mediator of GLP-1 therapy effects on liver health, particularly in patients with Type 2 Diabetes Mellitus. Understanding these mechani…
The review identified that GLP-1 RAs exert effects far beyond simple caloric restriction, significantly impacting neural circuits involved in reward processing and impulse control. They found that these agents can mod…
While specific quantitative results are not detailed in this summary, the study was designed to rigorously evaluate the efficacy of Liraglutide in a challenging patient population. The primary objective was to determi…
This feasibility study holds significant promise for improving the management of Atrial Fibrillation (AF) in overweight and obese individuals, a population often facing suboptimal outcomes. The key implication is that…
This research is significant because it addresses a critical health disparity, focusing on Mexican American women who are at elevated risk for type 2 diabetes. Improving beta cell function is a direct strategy to halt…
If the study's findings demonstrate positive effects on cardio-metabolic risk markers, it would reinforce Liraglutide's role as a multi-faceted treatment, offering significant cardiovascular benefits beyond glucose co…
The study revealed differential impacts on heart failure (HF) risk among incretin-based drug classes. DPP-4 inhibitors were generally associated with a similar risk of HF compared to other oral anti-diabetic drugs; sp…